Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 3,121–3,130 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 3121

    Medicine slug
    fidaxomicin
    Medicine name
    Fidaxomicin
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:dd966338-c820-4270-b704-09ef75fa3ceb (opens source in a new tab)

      Fidaxomicin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vivo studies were conducted to evaluate intestinal drug-drug interactions of fidaxomicin as a P-gp substrate, P-gp inhibitor, and inhibitor of major CYP enzymes expressed in the gastrointestinal tract (CYP3A4, CYP2C9, and CYP2C19).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:dd966338-c820-4270-b704-09ef75fa3ceb (opens source in a new tab)

      Fidaxomicin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies In vivo studies were conducted to evaluate intestinal drug-drug interactions of fidaxomicin as a P-gp substrate, P-gp inhibitor, and inhibitor of major CYP enzymes expressed in the gastrointestinal tract (CYP3A4, CYP2C9, and CYP2C19).

  2. Projected row 3122

    Medicine slug
    fidaxomicin
    Medicine name
    Fidaxomicin
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:dd966338-c820-4270-b704-09ef75fa3ceb (opens source in a new tab)

      Fidaxomicin label

      Version not recorded · Effective date not recorded

      No dose adjustment is warranted when fidaxomicin is co-administered with substrates of P-gp or CYP enzymes.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:dd966338-c820-4270-b704-09ef75fa3ceb (opens source in a new tab)

      Fidaxomicin label

      Version not recorded · Effective date not recorded

      No dose adjustment is warranted when fidaxomicin is co-administered with substrates of P-gp or CYP enzymes. 12.4 Microbiology Mechanism of Action Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum.

  3. Projected row 3123

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    BCRP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Other Drugs : No clinically significant differences in the pharmacokinetics of the following drugs were observed or predicted when used concomitantly with finerenone: S-warfarin (CYP2C9 substrate), digoxin (P-gp substrate), and rosuvastatin (BCRP and OATP substrate).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Other Drugs : No clinically significant differences in the pharmacokinetics of the following drugs were observed or predicted when used concomitantly with finerenone: S-warfarin (CYP2C9 substrate), digoxin (P-gp substrate), and rosuvastatin (BCRP and OATP substrate).

  4. Projected row 3124

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP2C8
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      There was no clinically significant difference in finerenone pharmacokinetics when used concomitantly with gemfibrozil (strong CYP2C8 inhibitor).
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      There was no clinically significant difference in finerenone pharmacokinetics when used concomitantly with gemfibrozil (strong CYP2C8 inhibitor).

  5. Projected row 3125

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP2C8
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Metabolism Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Metabolism Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites.

  6. Projected row 3126

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP2C8
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      CYP2C8 Substrates: Concomitant use of multiple finerenone 40 mg doses once daily with repaglinide (sensitive CYP2C8 substrate) increased the mean AUC and C max of repaglinide by 59% and 30%, respectively.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      CYP2C8 Substrates: Concomitant use of multiple finerenone 40 mg doses once daily with repaglinide (sensitive CYP2C8 substrate) increased the mean AUC and C max of repaglinide by 59% and 30%, respectively.

  7. Projected row 3127

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP2C9
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Other Drugs : No clinically significant differences in the pharmacokinetics of the following drugs were observed or predicted when used concomitantly with finerenone: S-warfarin (CYP2C9 substrate), digoxin (P-gp substrate), and rosuvastatin (BCRP and OATP substrate).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Other Drugs : No clinically significant differences in the pharmacokinetics of the following drugs were observed or predicted when used concomitantly with finerenone: S-warfarin (CYP2C9 substrate), digoxin (P-gp substrate), and rosuvastatin (BCRP and OATP substrate).

  8. Projected row 3128

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP3A4
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Strong or Moderate CYP3A Inducers : Concomitant use of efavirenz (moderate CYP3A4 inducer) and rifampicin (strong CYP3A4 inducer) was predicted to decrease finerenone AUC by 80% and 90%, respectively.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Strong or Moderate CYP3A Inducers : Concomitant use of efavirenz (moderate CYP3A4 inducer) and rifampicin (strong CYP3A4 inducer) was predicted to decrease finerenone AUC by 80% and 90%, respectively.

  9. Projected row 3129

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    8
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors : Concomitant use of itraconazole (strong CYP3A4 inhibitor) was predicted to increase finerenone AUC by >400%.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Moderate CYP3A Inhibitors : Concomitant use of erythromycin (moderate CYP3A4 inhibitor) increased finerenone mean AUC and C max by 248% and 88%, respectively.
    3. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Concomitant use of verapamil (moderate CYP3A4 inhibitor) increased finerenone mean AUC and C max by 170% and 122%, respectively.
    4. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Weak CYP3A Inhibitors : Concomitant use of amiodarone (weak CYP3A4 inhibitor) increased finerenone AUC by 21%.
    5. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A Inhibitors : Concomitant use of itraconazole (strong CYP3A4 inhibitor) was predicted to increase finerenone AUC by >400%.
    6. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Moderate CYP3A Inhibitors : Concomitant use of erythromycin (moderate CYP3A4 inhibitor) increased finerenone mean AUC and C max by 248% and 88%, respectively.
    7. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Concomitant use of verapamil (moderate CYP3A4 inhibitor) increased finerenone mean AUC and C max by 170% and 122%, respectively.
    8. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Weak CYP3A Inhibitors : Concomitant use of amiodarone (weak CYP3A4 inhibitor) increased finerenone AUC by 21%.

  10. Projected row 3130

    Medicine slug
    finerenone
    Medicine name
    Finerenone
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Metabolism Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      CYP3A4 Substrates: Concomitant use of multiple finerenone 40 mg doses once daily with midazolam (sensitive CYP3A4 substrate) increased the mean AUC by 31% with no effect on C max .
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      Metabolism Finerenone is primarily metabolized by CYP3A4 (90%) and to a lesser extent by CYP2C8 (10%) to inactive metabolites.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:fc726765-5d5a-4d6e-b037-b847bda9fb7c (opens source in a new tab)

      Finerenone label

      Version not recorded · Effective date not recorded

      CYP3A4 Substrates: Concomitant use of multiple finerenone 40 mg doses once daily with midazolam (sensitive CYP3A4 substrate) increased the mean AUC by 31% with no effect on C max .

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=3120

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy
Enzyme and transporter findings | RNAWiki